title: Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
abstract: We investigated the serum levels of both receptor activator of nuclear factor kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG) in postmenopausal healthy women after a 1-yr therapy with genistein, (n = 30; 54 mg/d), hormone replacement therapy (n = 30; 1 mg/d 17beta-estradiol combined with norethisterone acetate) and placebo (n = 30). By comparison with placebo, the soluble RANKL (sRANKL)/OPG ratio was lower in the genistein group (-69 +/- 7%; P < 0.01 vs. placebo 81 +/- 24%) and in hormone replacement therapy-treated women (-11 +/- 2%; P < 0.01 vs. placebo). A positive correlation (r = 0.63; P < 0.01) was found between 1-yr percentage change in sRANKL/OPG ratio and 1-yr change in urinary deoxypyridinoline, a bone resorption marker. A negative correlation was observed between 1-yr percentage change in sRANKL/OPG ratio and 1-yr change in femoral neck bone mineral density (r = -0.7; P < 0.01). Our findings suggest that the sRANKL-OPG system may mediate the beneficial effects of genistein on bone remodeling in postmenopausal women.
authors.affiliation: Department of Biomedical Sciences, Section of Pharmacology, University of Modena and Reggio Emilia, 41100 Modena, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Crisafulli
authors.forename: Domenica
authors.initials: D
authors.lastname: Altavilla
authors.forename: Giovanni
authors.initials: G
authors.lastname: Squadrito
authors.forename: Adolfo
authors.initials: A
authors.lastname: Romeo
authors.forename: Elena B
authors.initials: EB
authors.lastname: Adamo
authors.forename: Rolando
authors.initials: R
authors.lastname: Marini
authors.forename: Maria A
authors.initials: MA
authors.lastname: Inferrera
authors.forename: Herbert
authors.initials: H
authors.lastname: Marini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Bitto
authors.forename: Rosario
authors.initials: R
authors.lastname: D'Anna
authors.forename: Francesco
authors.initials: F
authors.lastname: Corrado
authors.forename: Sebastiano
authors.initials: S
authors.lastname: Bartolone
authors.forename: Nicola
authors.initials: N
authors.lastname: Frisina
authors.forename: Francesco
authors.initials: F
authors.lastname: Squadrito
mesh_terms: D000596:Amino Acids / Q000652:urine; D015519:Bone Density; D016723:Bone Remodeling; D001862:Bone Resorption; D002352:Carrier Proteins / Q000097:blood*; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy; D005260:Female; D005272:Femur Neck; D019833:Genistein / Q000008:administration & dosage*; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077563:Norethindrone Acetate; D053244:Osteoprotegerin; D010919:Placebos; D017698:Postmenopause; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood*; D018124:Receptors, Tumor Necrosis Factor
chemical_list: D000596:Amino Acids; D002352:Carrier Proteins; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D053244:Osteoprotegerin; D010919:Placebos; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D004958:Estradiol; C036020:deoxypyridinoline; D000077563:Norethindrone Acetate; D019833:Genistein; D009640:Norethindrone